Health & Bio

Novo oral Wegovy overpowers Lilly's Foundayo 6.7-to-1 in scripts, seizes market

Last week of April: Novo oral semaglutide 135K prescriptions vs Lilly Foundayo 20K. 17% weight loss vs 12% gap hands oral GLP-1 to Novo.

Primary sources · 2
CNBCFierce Pharma
Related storylines
#2026-W14-04 · GLP-1 market enters triple inflection point: oral agents, insurance cliff, and end of 503B compounding
← View the full 2026-05-15 (Fri) issue
What you're reading now arrives in your inbox daily at 21:00 UTC.

Get today's brief every day at 21:00 UTC

7 must-reads · 17 fields · tracked storylines delivered to your inbox daily. Pick only the fields you want; unsubscribe anytime.

Past issues →